Clinical Trial

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

Study acronym: HEMA-MED
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with Myelofibrosis. The main questions it aims to answer is to evaluate the safety and tolerability of roginolisib when administered in combination with ruxolitinib.
Protocol Amendment History 1 change
notable Trial sites expanded: 7 -> 11 locations 2026-04-28
Trial Details
NCT Number NCT06887803
Lead Sponsor iOnctura
Conditions Myelofibrosis (MF)
Enrollment 26 participants
Start Date 2025-11-17
Primary Completion 2028-03 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-23